seedfolio investments and their mpact
FUND 2 INVESTMENTS
ACQUIRED. Improving lower pelvic surgeries with faster safer ureter identification
AmplifiDx: Faster and 10x cheaper than PCR. The next point-of-care molecular diagnostics platform.
Amplo is treating diseases of the neuro-muscular junction (including congenital myasthenia syndrome, ALS, and muscular dystrophies) by one-time Dok7-gene therapy
Anvil uses existing ultrasensitive dPCR, but tricks it out to turn 6 channels into 63 for specific-pathogen identification. Sepsis path ID in 2 hours at POC instead of 2 days by culture.
Basilard has a novel mechanoporation device for non-viral ex-vivo transfection with greater efficiency and cell viability than electroporation.
Califia Pharma: The inventor of irofulven has developed a better/safer version and precision-medicine approach to treat multiple cancer types
Chronus is developing the first point-of-care device to measure both CBC and CMP in minutes at high accuracy and low cost. CBC and CMP account for 50% of all lab tests and $9b of market size.
Delpor’s platform delivers drugs at stable levels for up to 12 months from a single implant.
Duo Oncology has novel polymeric micelles small enough (15nm) to penetrate stroma in tumors (like pancreatic) and deliver proven payloads.
Earthgrid has “groundbreaking” tunnel-boring technology to allow renewable projects to more easily connect to the grid.
eGlint has a novel detection approach to leverage aptamers for fast, low-cost, high-accuracy, high-multiplex diagnostics
Ekefalos is developing cyclotides to deliver proteins (enzymes, antibodies, growth factors) across the blood brain barrier
Portable solar/battery towers for lights/comms/security, with no tow-hitch needed. Elegant design. Compact package. Industrial ruggedness. For construction, military/first-responders, sports, and events.
Hap10 is developing antibodies targeting haptens of inhibited KRAS12C. From the UCSF Labs of Charles Craik and Kevan Shokat.
HDAX Therapeutics has potent, bitopic-binding small molecule inhibitors of HDAC6 for neurologic (CMT, CIPN, ALS) and cardiovascular indications.
Hervolution has a novel cancer vaccine targeting human endogenous retrovirus
Himalaya Therapeutics has xclusive access in China to BioAtla’s “CAB” therapeutics to treat cancer
Interface Bioscience uses AI and secret sauce to map the full metabolome of the human microbiome (skin and gut) and use this novel library and data to find novel immunomodulating agents. They are starting with eczema and then IBD.
Innova Vascular has FDA-cleared minimally invasive devices that retrieve and aspirate clots in legs (DVT) or lungs (PE).
Ivy Energy provides an “Easy Button” for landlords to leverage VNEM to profitably add solar to their apartments.
Leap has a revolutionary process to manufacture solar cells without wafers
Life Detection Technologies prevents hospitalization by predicting COPD exacerbations through non-contact overnight monitoring of heart and respiration rates.
Lilium has achieved the trifecta of in-vivo gene delivery (cell-specific targeting, no liver sink, no immunogenicity)
Maxwell Biomedical is developing an electronic implantable device to correct atrial fibrillation
Myogenica is advancing progenitor muscle stem cells to treat muscular dystrophies.
NanoPharma Solutions increases the solubility of drugs without solvents or stabilizers. Great for intranasal and inhalable formulations.
Novel Biotechnology manufactures DNA plasmids using a proprietary bacterial strain. A drop-in replacement for e. coli, it can produce challenging plasmids at higher yield in less time.
Ordaos has a best-in-class team and AI system to generate mini proteins. Compared to typical antibody screening, they deliver leads with 1000x more affinity in 1/10th the time.
Particella has novel lipid nanoparticles for ORAL delivery of mRNA to the intestine
Palm Therapeutics has developed a novel, rapid screening system to find protein-specific inhibitors of palmitoylation. First target is pan-NRAS-mutant cancers.
PercAssist is developing the first minimally invasive heart-assist device
Preview Medical is improving the diagnosis and treatment of prostate cancer
Progentos is developing a small molecule to reverse the course of multiple sclerosis.
Pulmair is developing stents for lungs to keep airways open
Pyrojas is developing personalized, durable, effective cancer vaccines—with a twist. They isolate a patient’s cancer cells, genetically and chemically modify them, and reinject them into the patient.
RecoverX has AI (without hallucinations) for differntial diagnosis at point of care, based on ground truth like JAMA and BMJ, helping clinicians make better faster diagnoses
Regenosine delivers natural adenosine to regrow cartilage to reverse arthritis.
Remedium has developed a novel gene therapy delivery platform. They load DNA into proprietary LNPs, inject those subcutaneously, and turn fat cells into protein factories. For just one example: a single injection to produce stable GLP1 for 3+ years. Unique among gene therapies, they can later adjust the dose up or DOWN.
Renovo Rx is in Phase 3 trials of their drug-device combo that delivers chemo to a tumor site via a minimally invasive catheter. Interim results show a doubling of PFS and reduced toxicity in locally advanced pancreatic cancer.
Resynergi is converting waste plastic into diesel or naptha (raw material for plastic) by microwave pyrolysis
Ruby has Robotics and AI to autonomously prepare, image and assess tissue during biopsy procedures
S2 Genomics is developing a device to process solid tissues into single-cells or nuclei for sequencing
Sirpant quickly modifyies a patient’s own macrophages to elicit a broad-spectrum immune response to fight cancer locally and vaccinate systemically
Trio Pharmaceuticals is developing novel quadrivalent bi-specifics to fight cancer
Vasa Therapeutics is developing multiple novel therapies for vascular disease and heart failure
Veckta is building the leading global marketplace for design, optimization, and procurement of onsite energy systems
VerImmune is redirecting previously acquired viral immunity to fight cancer
Vian Therapeutics has an eyedrop (not injection into the eye) that can potently treat wet AMD and DME to disrupt a $15b market.
FUND 1b INVESTMENTS
Reprogram patient's immune cells within the patient, aka in vivo CAR-T
Wireless broadband for parks enables modern families to get outdoors more.
Matching patients who are leaving the acute-health-care system with appropriate long-term care providers
Repurposing a proven, potent NSAID into a topical treatment for arthritis.
Revolutionary orthodontics. Much faster result than traditional braces or Invisalign. (previously Mechanodontics)
Using AI to inspect pictures of energy assets (like power lines) to find faults, avoid fires and outages, and save utilities money
Developing a novel hernia-repair device to greatly reduce the currently high rate of hernia-repair failure
ACQUIRED. Revolutionizing microscopes to change how science is viewed.
Hacking opiod pills to 1) make overdosing impossible and 2) reduce shelf life to avoid post-prescription use
Developing 3D virtual labs for STEM education
Building a disruptive marketplace for life-science research supplies
Developing and selling a platform to allow health-care providers to remotely monitor patients using vendor-agnostic hardware
Nutritional system to prevent food allergies in children
Building a 2-sided bidding portal that simplifies the sourcing and analysis of complex clinical study proposals
AI-driven testing to accelerate software development.
FUND 1a INVESTMENTS
IPOd. Novel, safe inhibitor of GSK-3b to fight cancer and fibrotic diseases
Bacteria eat sugar in wastewater to treat water and generate electricity. Big savings for food & beverage companies.
ACQUIRED by Novartis in a $1b deal. Technology to enable delivery of siRNA therapies
Advancing recycling with AI and robots.
The only wireless underground moisture sensor so farmers can irrigate optimally.
A treatment that turns a common local tumor ablation into a systemic immunotherapy for cancer.
Developing IOT and AI solutions to predict failures, improve maintenance, and optimize fuel for maritime fleets
Bioengineered human lubricin to fight dry eye and arthritis.
Software for faster, more accurate data capture in clinical trials.
ACQUIRED. Developed a collaborative online learning platform
ACQUIRED. Developed rapid genetic testing of cancer-biopsy samples.
Accelerating drug and biology research through robotic automation
Developing IOT and AI solutions to improve the safety and efficiency of trucking fleets.
ACQUIRED. Analytics for water utilities to engage customers on their water usage